OpenEvidence Secures $250M, Valuation Soars to $12 Billion
January 23, 2026, 9:39 pm
OpenEvidence, an AI-powered medical platform, closed a $250 million Series D round. It now stands at a $12 billion valuation, becoming the highest-valued healthcare AI company. This funding, co-led by Thrive Capital and DST Global, propels research and development. OpenEvidence offers doctors real-time, evidence-based answers, synthesized from peer-reviewed literature. It serves over 40% of U.S. physicians, enabling 18 million monthly consultations. The company achieved $100 million in annual revenue. Its ad-supported model is free for doctors. This strategic move strengthens OpenEvidence's dominant position in clinical intelligence, aiming to enhance patient care and physician efficiency.
OpenEvidence has redefined medical intelligence. The company recently announced a significant financial milestone. It secured $250 million in Series D funding. This round catapults its valuation to $12 billion. OpenEvidence now holds the title of the highest-valued healthcare artificial intelligence firm. Thrive Capital and DST Global spearheaded the investment.
This latest capital infusion brings OpenEvidence's total funding over the past year to nearly $700 million. A diverse group of prominent investors has backed the company. These include Sequoia, Google Ventures, Nvidia, and Mayo Clinic. The substantial funding underscores strong market confidence. It validates OpenEvidence's innovative approach to healthcare technology.
The Miami-based company built a specialized AI platform. It functions as a "brain extender" for clinicians. Doctors access real-time answers. These responses are precisely synthesized from peer-reviewed medical literature. Each answer includes direct citations. This ensures accuracy and verifiability. OpenEvidence is unique in its data training. Its AI models learn exclusively from medical journals and data. It avoids the broader internet. This focus prevents misinformation.
New funds will primarily fuel research and development. They will also cover significant compute costs. OpenEvidence employs a "multi-agent" AI architecture. This system orchestrates multiple medically specialized AI models. A central coordinating model routes questions. It directs them to the most relevant sub-specialty AI. This sophisticated design ensures highly accurate and contextual responses.
OpenEvidence demonstrates remarkable growth metrics. Over 100 million Americans received treatment from a doctor using the platform last year. In December 2025 alone, the system supported approximately 18 million clinical consultations. These interactions came from logged-in, verified U.S. doctors. This represents a substantial increase from roughly 3 million per month just a year prior. An independent report confirmed its dominance. OpenEvidence is reportedly used by more American physicians than all other AI tools combined. More than 40% of U.S. physicians rely on the platform.
The company operates on a unique revenue model. It offers its platform free to doctors. Revenue is generated through an ad-supported system. This strategy facilitates widespread adoption. It removes financial barriers for individual practitioners. OpenEvidence reported achieving $100 million in annual revenue. This milestone was reached less than a year after establishing its commercial team. This ad-based approach is gaining traction even among larger AI players.
OpenEvidence extends beyond basic search. Its tools help doctors rapidly grasp new medical guidelines. It highlights changes between editions. The platform also serves as a clinical education resource. Medical schools utilize it for exam generation. Students use it as a study aid. Prompt responses consistently include citations. This allows users to verify and delve deeper into topics. The company also offers a tool for creating medical notes. This feature enriches notes with external healthcare data.
The healthcare AI landscape is competitive. OpenEvidence is often dubbed "ChatGPT for doctors." Other major players are entering the space. OpenAI launched "ChatGPT Health." Anthropic offers "Claude Healthcare." OpenEvidence maintains a strong competitive moat. Its exclusive focus remains on physicians. It boasts superior data quality. The company also leverages a significant first-mover advantage. This includes a vast repository of real-world clinical consultations. These verified physician interactions create an invaluable feedback loop. This data is incredibly difficult for competitors to replicate.
Founder and CEO Daniel Nadler leads OpenEvidence. Nadler previously built Kensho Technologies. S&P acquired Kensho for approximately $700 million. His vision for OpenEvidence is ambitious. He aims to build a standalone company. This strategy contrasts with prior acquisition routes. The company prioritizes balanced growth with eventual profitability. It avoids aggressive spending common among some AI startups.
The long-term outlook for OpenEvidence is strong. It plays a critical role in modernizing medical practice. Its commitment to evidence-based AI improves patient care. It enhances physician efficiency. The company’s robust funding and rapid adoption signal a powerful trajectory. OpenEvidence is poised for continued leadership in the evolving healthcare AI sector. Future plans include exploring additional healthcare applications. These would further leverage its extensive physician user base. An initial public offering could follow. This would likely occur after "foundation model companies" establish their public market presence.
The impact of OpenEvidence resonates across the healthcare continuum. It addresses a critical need. Physicians face an overwhelming volume of new medical information. OpenEvidence provides a vital tool. It helps them stay current. It ensures access to the latest evidence. This ultimately translates to better patient outcomes. The company's innovative model and sustained growth mark it as a transformative force. Its presence ensures that advanced AI serves the very front lines of medicine. OpenEvidence is setting new standards for clinical intelligence.
OpenEvidence has redefined medical intelligence. The company recently announced a significant financial milestone. It secured $250 million in Series D funding. This round catapults its valuation to $12 billion. OpenEvidence now holds the title of the highest-valued healthcare artificial intelligence firm. Thrive Capital and DST Global spearheaded the investment.
This latest capital infusion brings OpenEvidence's total funding over the past year to nearly $700 million. A diverse group of prominent investors has backed the company. These include Sequoia, Google Ventures, Nvidia, and Mayo Clinic. The substantial funding underscores strong market confidence. It validates OpenEvidence's innovative approach to healthcare technology.
The Miami-based company built a specialized AI platform. It functions as a "brain extender" for clinicians. Doctors access real-time answers. These responses are precisely synthesized from peer-reviewed medical literature. Each answer includes direct citations. This ensures accuracy and verifiability. OpenEvidence is unique in its data training. Its AI models learn exclusively from medical journals and data. It avoids the broader internet. This focus prevents misinformation.
New funds will primarily fuel research and development. They will also cover significant compute costs. OpenEvidence employs a "multi-agent" AI architecture. This system orchestrates multiple medically specialized AI models. A central coordinating model routes questions. It directs them to the most relevant sub-specialty AI. This sophisticated design ensures highly accurate and contextual responses.
OpenEvidence demonstrates remarkable growth metrics. Over 100 million Americans received treatment from a doctor using the platform last year. In December 2025 alone, the system supported approximately 18 million clinical consultations. These interactions came from logged-in, verified U.S. doctors. This represents a substantial increase from roughly 3 million per month just a year prior. An independent report confirmed its dominance. OpenEvidence is reportedly used by more American physicians than all other AI tools combined. More than 40% of U.S. physicians rely on the platform.
The company operates on a unique revenue model. It offers its platform free to doctors. Revenue is generated through an ad-supported system. This strategy facilitates widespread adoption. It removes financial barriers for individual practitioners. OpenEvidence reported achieving $100 million in annual revenue. This milestone was reached less than a year after establishing its commercial team. This ad-based approach is gaining traction even among larger AI players.
OpenEvidence extends beyond basic search. Its tools help doctors rapidly grasp new medical guidelines. It highlights changes between editions. The platform also serves as a clinical education resource. Medical schools utilize it for exam generation. Students use it as a study aid. Prompt responses consistently include citations. This allows users to verify and delve deeper into topics. The company also offers a tool for creating medical notes. This feature enriches notes with external healthcare data.
The healthcare AI landscape is competitive. OpenEvidence is often dubbed "ChatGPT for doctors." Other major players are entering the space. OpenAI launched "ChatGPT Health." Anthropic offers "Claude Healthcare." OpenEvidence maintains a strong competitive moat. Its exclusive focus remains on physicians. It boasts superior data quality. The company also leverages a significant first-mover advantage. This includes a vast repository of real-world clinical consultations. These verified physician interactions create an invaluable feedback loop. This data is incredibly difficult for competitors to replicate.
Founder and CEO Daniel Nadler leads OpenEvidence. Nadler previously built Kensho Technologies. S&P acquired Kensho for approximately $700 million. His vision for OpenEvidence is ambitious. He aims to build a standalone company. This strategy contrasts with prior acquisition routes. The company prioritizes balanced growth with eventual profitability. It avoids aggressive spending common among some AI startups.
The long-term outlook for OpenEvidence is strong. It plays a critical role in modernizing medical practice. Its commitment to evidence-based AI improves patient care. It enhances physician efficiency. The company’s robust funding and rapid adoption signal a powerful trajectory. OpenEvidence is poised for continued leadership in the evolving healthcare AI sector. Future plans include exploring additional healthcare applications. These would further leverage its extensive physician user base. An initial public offering could follow. This would likely occur after "foundation model companies" establish their public market presence.
The impact of OpenEvidence resonates across the healthcare continuum. It addresses a critical need. Physicians face an overwhelming volume of new medical information. OpenEvidence provides a vital tool. It helps them stay current. It ensures access to the latest evidence. This ultimately translates to better patient outcomes. The company's innovative model and sustained growth mark it as a transformative force. Its presence ensures that advanced AI serves the very front lines of medicine. OpenEvidence is setting new standards for clinical intelligence.